Stocks · News reference
Galmed Pharma Announces Continued Advancement Of Aramchol As Potential Disease-Modifying Therapy For Parkinson's Disease, Reporting Significant Progress In Development Of New Aramchol ODF Formulation
Aramchol meglumine is the only SCD1 inhibitor with an established clinical safety profile and confirmed blood-brain barrier (BBB) penetration.In order to improve patient convenience and long-term treatment adherence by
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Galmed Pharmaceuticals Announces Rebrand To Eocene And Nasdaq Ticker Change From GLMD To EOCN Effective September 10; Announces Termination Of Yorkville Standby Equity Purchase Agreement Effective September 8
Galmed Pharmaceuticals shares are trading higher after the company's subsidiary Colospan announced the completion of a feasibility study supporting the development of a novel intraoperative colon tissue quality assessment platform.
Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times